



DECEMBER 11-12, 2025  
۲۱ و ۲۰ آذر ماه ۱۴۰۴



دومین کنگره  
پلازما پزشکی ایران

The 2<sup>nd</sup> Congress on Plasma Medicine

دبیرخانه دائمی کنگره  
پلازما پزشکی ایران  
www.plasmamedsym.ir



# Efficacy of Cold Plasma in Stimulating Hippocampal Neurogenesis in Patients with Early-Stage Parkinson's Disease with the Mediating Role of *BDNF* Gene Expression and Cognitive Performance

Mohammad Hossein Roudbari

Department of Clinical Psychology, Faculty of Medicine, Islamic Azad University, Kish Island, Iran

## OPEN ACCESS

### Citation:

Roudbari MH. Efficacy of Cold Plasma in Stimulating Hippocampal Neurogenesis in Patients with Early-Stage Parkinson's Disease with the Mediating Role of *BDNF* Gene Expression and Cognitive Performance. *Iran Biomed J. Supplementary* (2-2026): 54.

## ABSTRACT

**Introduction:** Early-stage Parkinson's disease is associated with the loss of dopaminergic neurons and impaired hippocampal neurogenesis, leading to cognitive deficits. Cold atmospheric plasma (CAP), a novel intervention, exhibits anti-inflammatory and stimulatory effects on neural cells. Brain-derived neurotrophic factor (*BDNF*) plays a pivotal role in hippocampal neurogenesis. This study investigated the efficacy of CAP in stimulating hippocampal neurogenesis in patients with early-stage Parkinson's disease, examining the mediating roles of *BDNF* gene expression and cognitive performance.

**Materials and Methods:** A quasi-experimental study with a pretest-posttest control group design was conducted in neurology clinics in Tehran. The sample consisted of 60 patients with early-stage Parkinson's disease (30 in the intervention group and 30 in the control group), all at Hoehn-Yahr stages 1–2. The intervention group received 12 sessions of 20-minute each of CAP (dose: 10 kV/cm) applied to the scalp, especially the temporal region. The assessment tools included the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination for cognitive evaluation, quantitative polymerase chain reaction for measuring peripheral blood *BDNF* gene expression, and hippocampal MRI to measure the volume of the dentate gyrus (DG). Data were analyzed using structural equation modeling (SEM) in AMOS.

**Results and Discussion:** Post-intervention, neurogenesis (based on DG volume) increased by 28% ( $p < 0.001$ ). *BDNF* gene expression mediated 35% ( $\beta = 0.35$ ) and cognitive performance (with MoCA score improving from 22.4 to 26.7) mediated 42% ( $\beta = 0.42$ ), both of which were statistically significant. SEM confirmed the indirect pathway: CAP → *BDNF* → neurogenesis (GFI = 0.95; RMSEA=0.06). No adverse events were reported during the study.

**Conclusion:** CAP is a safe and effective approach for stimulating hippocampal neurogenesis in early-stage Parkinson's disease, acting through *BDNF*. It is recommended that CAP be integrated into clinical treatment protocols.



This article is licensed under a Creative Commons Attribution-NonDerivatives 4.0 International License.

**Keywords:** *BDNF*, Cognitive performance, Cold plasma, Hippocampal neurogenesis, Parkinson's disease

**Corresponding Author:** Mohammad Hossein Roudbari

Department of Clinical Psychology, Faculty of Medicine, Islamic Azad University, Kish Island, Iran; E-mail: mroudbari9@gmail.com



Iranian Biomedical Journal Supplementary (February 2026): 54